NEW YORK, NY / ACCESSWIRE / March 8, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Tricida, Inc. (NASDAQ:TCDA)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/tricida-inc-loss-submission-form?prid=13406&wire=1
Lead Plaintiff Deadline: March 8, 2021
Class Period: September 4, 2019 - October 28, 2020
Allegations against TCDA include that: (i) Tricida's NDA for veverimer was materially deficient; (ii) accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Exxon Mobil Corporation (NYSE:XOM)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/exxon-mobil-corporation-loss-submission-form?prid=13406&wire=1
Lead Plaintiff Deadline: March 29, 2021
Class Period: February 28, 2018 - January 14, 2021
Allegations against XOM include that: (i) Exxon forced its employees to use unrealistic assumptions regarding the timelines for well drilling in the Permian Basin; (ii) the foregoing assumptions served to artificially inflate the value of the Company's well operations in the Permian Basin; (iii) the foregoing conduct, when revealed, subjected Exxon to a heightened risk of regulatory investigation and oversight; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Athenex, Inc. (NASDAQ:ATNX)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/athenex-inc-loss-submission-form?prid=13406&wire=1
Lead Plaintiff Deadline: May 3, 2021
Class Period: August 7, 2019 - February 26, 2021
Allegations against ATNX include that: Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the data included in the Oral Paclitaxel plus Encequidar NDA presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (ii) the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by BICR; (iii) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (iv) that the Company's Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; (v) as a result, it was foreseeable that the FDA would not approve the Company's NDA in its current form; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong